Decreasing salt intake may benefit patients with nocturia who are heavy salt users, according to a new study published in Neurourology and Urodynamics. In a prospective study, Tomohiro Matsuo, MD, and colleagues from Nagasaki University Graduate School of Biomedical Sciences in Nagasaki, Japan, analyzed changes in lower urinary tract symptoms in 321 patients with nocturia…
In a small trial, patients receiving 300 U and 500 U of intravesical abobotulinumtoxin A experienced reductions in nocturia episodes at 12 and 24 weeks.
In a study, percutaneous tibial nerve stimulation reduced nocturia episodes by 0.8 on average.
Nocturia improved 43% in patients receiving oral desmopressin alone and 64.3% in those receiving desmopressin and an alpha-blocker.
Desmopressin reduced the number of nocturnal voids by 0.85 compared with placebo.
Men with nocturia have a 1.4-fold greater risk of death than men without nocturia, after adjustment for age and major comorbidities.
The antidiuretic effects of desmopressin are mediated by stimulation of vasopressin 2 (V2) receptors, thereby increasing water reabsorption in the kidneys, and reducing urine production.
Lowering nocturnal urine production and enabling patients to void consistently at capacity may ease nocturia in men with low bladder capacity.
For men with nocturnal polyuria, the rate of urine production dropped off as the night progressed.
International Continence Society (ICS) standards offer useful guidance for nocturia management, according to the authors of a new report.
